Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
Date:3/3/2009

PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered a second Phase II clinical trial.

This Phase II trial with NXL104/ceftazidime will be in hospitalized patients with complicated intra-abdominal infections (cIAIs). In 2007, Novexel estimates that more than 300,000 patients were treated for cIAIs in hospital in the seven major pharmaceutical markets. This estimate is based on national databases providing hospital patient discharge data.

NXL104/ceftazidime is being developed to treat hospital infections that are caused by Gram negative bacteria, including those resistant to many currently used antibiotics. This Phase II trial is a prospective, multicenter, double-blind, randomized study which is designed to evaluate the efficacy, safety, and tolerability of NXL104/ceftazidime plus metronidazole vs. meropenem (Merrem(R) or Meronem(R), AstraZeneca, NYSE: AZN) in the treatment of adults with cIAIs. Complicated intra-abdominal infections include those infections requiring surgical intervention and which extend beyond the hollow viscus into the peritoneal space. A total of approximately 200 patients will be enrolled, with 100 patients being included in each treatment arm.

The primary objective of the study is to evaluate the clinical response to NXL104/ceftazidime plus metronidazole in the treatment of adult patients with cIAIs as compared to meropenem. This evaluation will be based on the Test of Cure visit two weeks post-therapy. T
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... FRANCISCO, Calif. , July 28, 2014 ... provided an update on the status of the KB001-A ... with Sanofi Pasteur.  KB001-A Collaboration ... an agreement with Sanofi Pasteur to regain all rights ... and licensing agreement entered into in 2010 has been ...
(Date:7/28/2014)... July 28, 2014 Reportlinker.com announces that ... its catalogue: Portugal Pharmaceuticals and ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 ... Faster-than-expected economic growth last quarter has led us ... upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... 2014  Air Products (NYSE: APD ) ... is vital to any healthcare facility. This understanding has ... improve the efficiency of its oxygen supply systems, but ... systems—including systems for emergency oxygen supply and ... at the 51 st ASHE Annual Conference ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3
(Date:7/28/2014)... school students seem to be satisfied with the healthier school ... of school officials. , , New meal standards -- issued ... in the fall of 2012. At the time, there was ... most of their food. But the new study of nearly ... , "The updated meals standards are resulting in healthier meals ...
(Date:7/28/2014)... 2014 Ticket Down is reliable ... in Dallas, TX at the Cotton Bowl. The 2014 ... USA and it is an eight team tourney. The ... including teams from La Liga, Serie A, English Premier League, ... it out on the pitch include: Manchester United, Manchester ...
(Date:7/28/2014)... 28, 2014 Shofner Vision Center ... June . Renowned LASIK and Cataract Surgeon, Dr. ... significant funds and public awareness for local not-for-profit ... personnel and their families. “This was our 2nd ... nearly $5,000 to a variety of local not-for-profit ...
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... are at risk of contracting meningitis because of specific ... to updated recommendations from the largest pediatrician group in ... the potentially deadly infection should continue for adolescents and ... In its first statement on meningococcal vaccines since 2011, ...
Breaking Medicine News(10 mins):Health News:Healthy School Lunches Get Thumbs Up From Students 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3
... incidents at the nation’s hospitals rose three percent over ... hospitals had a 40 percent lower rate of medical ... the largest annual study of patient-safety issued today by ... ,The HealthGrades study of 40.56 million Medicare hospitalization ...
... figure out the words' meaning for themselves, research by a ... an undergraduate student in the John Hopkins University and who ... by inference is more powerful for 3-year-olds than just being ... that is particularly exciting about the work Meredith is doing ...
... A homeopathic treatment for cancer is under trial at a ... it would pass muster in the next six months., ... homeopathic medicine have already begun in the United States and ... its efficacy," Dr Susanta K Banerjee, a professor of haematology ...
... the state children’s health insurance program (SCHIP), teens ... eliminated and more preventive care is received. This ... their health care providers about guns, smoking, drugs, ... their long-term health. ,"Adolescents have the ...
... For the first time ever, a team of Toronto ... tests //to screen high-risk pregnant mothers for placental damage. ... be reassured that their placenta is formed and functioning ... tests are done early enough, at 16 to 23 ...
... endogenous pain-inhibitory function and increases spontaneous pain in women//. ... in chronic pain, according to a study published in ... ,The study, conducted by Michael T. Smith, PhD, and ... females, who were studied polysomnographically for seven nights. On ...
Cached Medicine News:Health News:Hospital Errors Rise 3 Percent -- HealthGrades Patient-safety Study 2Health News:Hospital Errors Rise 3 Percent -- HealthGrades Patient-safety Study 3Health News:Learning Words by Inference More Powerful for Toddlers 2Health News:Teens Get Needed Access to Care With State Health Insurance 2Health News:Teens Get Needed Access to Care With State Health Insurance 3Health News:New Placenta Screening for High-risk Pregnancies 2Health News:New Study in SLEEP Finds That Sleep Disturbance Increases Spontaneous Pain in Women 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: